B. Braun OEM Division - System-built Solutions. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

B. Braun OEM Division – System-built Solutions.

Expertise in contract manufacturing and infusion therapy products

B. Braun supplies healthcare markets worldwide and is employing approx. 48,000 individuals. Based on this expertise the B. Braun OEM Division serves the pharmaceutical and medical devices industry.

At B. Braun OEM we offer contract manufacturing for infusion, irrigation and volume replacement solutions as well as standard injectables, anesthetics and dermatological products like creams, gels and pomades. Depending on the product requirements, we can fill in containers of different sizes, shapes and materials.

Furthermore, we provide a wide range of infusion therapy products. We supply all that is needed to admixture and infuse or inject a drug. You can order standard products or a customized version.

Partnering with us provides you with complete outsourcing knowledge. Our project management teams are the experts for individual customer ideas.

We can handle manufacturing projects and will customize a product or set according to your detailed specifications.

Products:

  • Pharmaceutical Solutions
  • Medical Devices
  • Products for Disinfection and Hygiene

Project management services:

  • Customized Products (modified characteristics, private label etc.)
  • Customized Sets Pharmaceutical
  • Contract Manufacturing
  • Common Development

B. Braun Melsungen AG
Website: www.bbraunoem.com
E-mail: info-europe@bbraunoem.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
30%
Breakthrough designations
9%
Protecting the supply chain
39%
Expedited reviews of drug submissions
9%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here